P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)-BASED INDUCTION VS PARENTERAL V-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

• R. M. Rifkin,
• C. L. Costello,
• R. E. Birhiray,
• S. Kambhampati,
• J. Richter,
• R. Abonour,
• H. C. Lee,
• Y. J. Kim,
• K. Ren,
• D. M. Stull,
• D. Cherepanov,
• K. Bogard,
• S. J. Noga,
• S. Girnius

Affiliations

R. M. Rifkin

1 Rocky Mountain Cancer Centers/US Oncology Research, Denver

C. L. Costello

2 Moores Cancer Center, University of California San Diego, La Jolla

R. E. Birhiray

3 Hematology Oncology of Indiana/American Oncology Network, Indianapolis

S. Kambhampati

4 Kansas City Veterans Affairs Medical Center, Kansas City

J. Richter

5 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York

R. Abonour

6 Indiana University School of Medicine, Indianapolis

H. C. Lee

7 MD Anderson Cancer Center, Houston, United States of America

Y. J. Kim

8 Data Analytics, Evidera, St-Laurent, Canada

K. Ren

9 Takeda Development Center Americas, Inc. (TDCA)

D. M. Stull

10 Takeda Pharmaceuticals U.S.A., Inc., Lexington

D. Cherepanov

9 Takeda Development Center Americas, Inc. (TDCA)

K. Bogard

10 Takeda Pharmaceuticals U.S.A., Inc., Lexington

S. J. Noga

9 Takeda Development Center Americas, Inc. (TDCA)

S. Girnius

11 TriHealth Cancer Institute, Cincinnati, United States of America